Therapeutic Antibodies Against Cancer

Hematology/Oncology Clinics of North America

Volumn 26, Issue 3, 2012, Pages 447-481

  Adler, Mark J ^a,b   Dimitrov, Dimiter S ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b San Diego Cancer Research Institute   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antibodies; Cancer; Efficacy; Immunogenicity; Safety; Therapeutics

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; BENDAMUSTINE; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CATUMAXOMAB; CETUXIMAB; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; FLUDARABINE; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IPILIMUMAB; OFATUMUMAB; OXALIPLATIN; PACLITAXEL; PALIVIZUMAB; PANITUMUMAB; PREDNISONE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; ASCITES; BASAL CELL CARCINOMA; BIOENGINEERING; BLEEDING; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLITIS; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CYTOLOGY; DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FLU LIKE SYNDROME; GASTROINTESTINAL CARCINOMA; GLIOBLASTOMA; HEPATITIS; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; INFECTION; KIDNEY CANCER; LARGE CELL LYMPHOMA; LIVER CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MALAISE; MALIGNANT ASCITE; MELANOMA; MONOTHERAPY; MUCOCUTANEOUS REACTION; MYOSITIS; NEOPLASM; NEPHRITIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; SKIN MANIFESTATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; UVEITIS;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 84859941928     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.02.013     Document Type: Review

References (234)

1. Dillman R.O. Cancer immunotherapy. Cancer Biother Radiopharm 2011, 26(1):1-64.
2. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
3. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol 2006, 6(5):343-357.
4. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006, 5(2):147-159.
5. Waldmann T.A. Immunotherapy: past, present and future. Nat Med 2003, 9(3):269-277.
6. Casadevall A., Dadachova E., Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2(9):695-703.
7. Carter P.J. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011, 317(9):1261-1269.
8. Dimitrov D.S. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010, 2(3):347-356.
9. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010, 28(9):917-924.
10. Leader B., Baca Q.J., Golan D.E. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008, 7(1):21-39.
11. Dimitrov D.S., Marks J.D. Therapeutic antibodies: current state and future trends-is a paradigm change coming soon?. Methods Mol Biol 2009, 525:1-27.
12. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008, 7(12):1001-1012.
13. Beck A., Reichert J.M. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011, 3(5):415-416.
14. Reichert J.M. Antibody-based therapeutics to watch in 2011. MAbs 2011, 3(1):76-99.
15. Reichert J.M. Metrics for antibody therapeutics development. MAbs 2010, 2(6):695-700.
16. Teicher B.A., Chari R.V. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011, 17(20):6389-6397.
17. Pasquetto M.V., Vecchia L., Covini D., et al. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011, 34(9):611-628.
18. Ricart A.D. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther 2011, 89(4):513-523.
19. Ricart A.D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011, 17(20):6417-6427.
20. Grillo-Lopez A.J. Rituximab: an insider's historical perspective. Semin Oncol 2000, 27(6 Suppl 12):9-16.
21. Maloney D.G. Mechanism of action of rituximab. Anticancer Drugs 2001, 12(Suppl 2):S1-S4.
22. Byrd J.C., Kitada S., Flinn I., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99(3):1038-1043.
23. Hilchey S.P., Hyrien O., Mosmann T.R., et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a " vaccinal effect" of rituximab. Blood 2009, 113(16):3809-3812.
24. Mathas S., Rickers A., Bommert K., et al. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000, 60(24):7170-7176.
25. Shan D., Ledbetter J., Press O. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000, 48:673-683.
26. Dillman R.O., Hendrix C.S. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003, 1(1):38-48.
27. Allison M. PML problems loom for Rituxan. Nat Biotechnol 2010, 28(2):105-106.
28. Paues J., Vrethem M. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol 2010, 48(4):291-293.
29. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(4):235-242.
30. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23(18):4079-4088.
31. Harting R., Venogopal P., Gregory S.A., et al. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007, 7(6):406-412.
32. Fischer K., Cramer P., Busch R., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011, 29(26):3559-3566.
33. Datta Y.H., Kampalath B., Binion D.G. Rituximab-induced remission of a gastric MALT lymphoma. Leuk Lymphoma 2004, 45(6):1297-1299.
34. Chong E.A., Svoboda J., Cherian S., et al. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk Lymphoma 2005, 46(9):1383-1386.
35. Kluin-Nelemans H.C., Doorduijn J.K. Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 2011, 48(3):208-213.
36. Fenot M., Quereux G., Brocard A., et al. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol 2010, 20(6):753-757.
37. Bennett M., Schechter G.P. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 2010, 47(2):143-147.
38. Dimopoulos M.A., Kastritis E., Roussou M., et al. Rituximab-based treatments in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009, 9(1):59-61.
39. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343(24):1750-1757.
40. Flinn I.W., Neuberg D.S., Grever M.R., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25(7):793-798.
41. Robak T., Dmoszynska A., Solal-Céligny P., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10):1756-1765.
42. McLaughlin P. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
43. Huhn D., von Schilling C., Wilhelm M., et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001, 98(5):1326-1331.
44. Nabhan C., Kay N.E. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin Med Insights Oncol 2011, 5:45-53.
45. Teeling J.L., Mackus W.J., Wiegman L.J., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006, 177(1):362-371.
46. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009, 183(1):749-758.
47. Li B., Zhao L., Guo H., et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009, 114(24):5007-5015.
48. Coiffier B., Lepretre S., Pedersen L.M., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008, 111(3):1094-1100.
49. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99(10):3554-3561.
50. Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10):1749-1755.
51. Lemery S.J., Zhang J., Rothmann M.D., et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010, 16(17):4331-4338.
52. Wierda W.G., Kipps T.J., Durig J., et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117(24):6450-6458.
53. Haskova Z., Whitacre M.N., Dede K.A., et al. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia. Br J Haematol 2012, 156(3):402-404.
54. Sondak V.K., Flaherty L.E. Targeted therapies: improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol 2011, 8(9):513-515.
55. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256):1734-1736.
56. Peggs K.S., Quezada S.A., Allison J.P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224:141-165.
57. Tivol E.A., Borriello F., Schweitzer A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547.
58. Peggs K.S., Quezada S.A., Chambers C.A., et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206(8):1717-1725.
59. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007, 12(7):864-872.
60. Hodi F.S. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
61. Schwartzentruber D.J. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
62. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526.
63. Di Giacomo A.M., Biagioli M., Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37(5):499-507.
64. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23(25):6043-6053.
65. Sondak V.K., Smalley K.S., Kudchadkar R., et al. Ipilimumab. Nat Rev Drug Discov 2011, 10(6):411-412.
66. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
67. Pauletti G., Dandekar S., Rong H., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000, 18(21):3651-3664.
68. Dowsett M., Bartlett J., Ellis I.O., et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003, 199(4):418-423.
69. Perez E.A., Suman V.J., Davidson N.E., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24(19):3032-3038.
70. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl 4):S3-S8.
71. Cho H.S., Mason K., Ramyar K.X., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421(6924):756-760.
72. Bashey A., Medina B., Corringham S., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113(7):1581-1588.
73. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
74. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2):117-127.
75. Junttila T.T., Akita R.W., Parsons K., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15(5):429-440.
76. Sliwkowski M.X., Lofgren J.A., Lewis G.D., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26(4 Suppl 12):60-70.
77. Weiner L.M., Adams G.P. New approaches to antibody therapy. Oncogene 2000, 19(53):6144-6151.
78. Gennari R., Menard S., Fagnoni F., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10(17):5650-5655.
79. Kumar R., Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001, 28(5 Suppl 16):27-32.
80. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
81. Slamon D. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
82. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(7):1800-1808.
83. Burstein H.J., Harris L.N., Marcom P.K., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003, 21(15):2889-2895.
84. Chia S., Clemons M., Martin L.A., et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006, 24(18):2773-2778.
85. Costa R.B., Kurra G., Greenberg L., et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010, 21(11):2153-2160.
86. Baselga J., Perez E.A., Pienkowski T., et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006, 11(Suppl 1):4-12.
87. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375(9712):377-384.
88. Jorgensen J.T. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010, 78(1):26-33.
89. Kelly H., Kimmick G., Dees E.C., et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006, 7(3):237-243.
90. Perez E.A., Suman V.J., Rowland K.M., et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005, 6(5):425-432.
91. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23(9):1147-1157.
92. Banerjee S., Flores-Rozas H. Monoclonal antibodies for targeted therapy in colorectal cancer. Cancer Biol Ther 2010, 9(8):563-571.
93. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3(2):65-71.
94. Eskens F.A., Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006, 42(18):3127-3139.
95. Choueiri T.K., Mayer E.L., Je Y., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011, 29(6):632-638.
96. Nalluri S.R., Chu D., Keresztes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300(19):2277-2285.
97. Hurwitz H.I., Saltz L.B., Van Cutsem E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011, 29(13):1757-1764.
98. Sandler A.B., Schiller J.H., Gray R., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009, 27(9):1405-1412.
99. Badgwell B.D., Camp E.R., Feig B., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008, 19(3):577-582.
100. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19(3):843-850.
101. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349(5):427-434.
102. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
103. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25(30):4779-4786.
104. Fuchs C.S., Marshall J., Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008, 26(4):689-690.
105. Hochster H.S., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008, 26(21):3523-3529.
106. Vincenzi B., Santini D., Russo A., et al. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 2009, 115(20):4849-4856.
107. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23(16):3697-3705.
108. Allegra C.J., Yothers G., O'Connell M.J., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011, 29(1):11-16.
109. de Gramont A., Van Cutsem E., Tabernero J., et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 2011, 29(Suppl 4). [abstract: 362].
110. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
111. Reck M., von Pawel J., Zatloukal P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(9):1804-1809.
112. Patel J.D., Hensing T.A., Rademaker A., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009, 27(20):3284-3289.
113. Patel J.D., Bonomi P., Socinski M.A., et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009, 10(4):252-256.
114. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
115. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28(20):3239-3247.
116. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29(10):1252-1260.
117. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605):2103-2111.
118. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26(33):5422-5428.
119. Escudier B., Bellmunt J., Negrier S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28(13):2144-2150.
120. Rini B.I., Halabi S., Rosenberg J., et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J Clin Oncol 2009, 27:18s.
121. Vredenburgh J.J., Desjardins A., Herndon J.E.2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
122. Desjardins A., Reardon D.A., Herndon J.E.2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008, 14(21):7068-7073.
123. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740.
124. Burger R., Brady M.F., Bookman M.A., et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010, 28(Suppl):18s. p. LBA1.
125. Kristensen G., Perren T., Qian W., et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 2011, 29(Suppl). [abstract: LBA5006].
126. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26(18):2992-2998.
127. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(12):1898-1903.
128. Xu L., Duda D.G., di Tomaso E., et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009, 69(20):7905-7910.
129. Miles D., Harbeck N., Escudier B., et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011, 29(1):83-88.
130. Kerr D.J., Young A.M. Targeted therapies: bevacizumab-has it reached its final resting place?. Nat Rev Clin Oncol 2011, 8(4):195-196.
131. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011, 305(5):487-494.
132. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000, 6(3):747-753.
133. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23(9):1803-1810.
134. Lenz H.J., Van Cutsem E., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006, 24(30):4914-4921.
135. Tsuchihashi Z., Khambata-Ford S., Hanna N., et al. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005, 353(2):208-209.
136. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27(12):2091-2096.
137. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048.
138. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345.
139. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(14):2311-2319.
140. Van Cutsem E., Kohne C.H., Lang I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29(15):2011-2019.
141. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634.
142. Maughan T.S., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377(9783):2103-2114.
143. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
144. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11(1):21-28.
145. Vermorken J.B., Herbst R.S., Leon X., et al. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008, 112(12):2710-2719.
146. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531.
147. Gatzemeier U., von Pawel J., Vynnychenko I., et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011, 12(1):30-37.
148. Lynch T.J., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28(6):911-917.
149. Giusti R.M., Shastri K.A., Cohen M.H., et al. FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007, 12(5):577-583.
150. Berlin J., Posey J., Tchekmedyian S., et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007, 6(6):427-432.
151. Martinelli E., De Palma R., Orditura M., et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009, 158(1):1-9.
152. Hecht J.R., Mitchell E., Neubauer M.A., et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010, 16(7):2205-2213.
153. Peeters M., Siena S., Van Cutsem E., et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009, 115(7):1544-1554.
154. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712.
155. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664.
156. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28(31):4697-4705.
157. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(31):4706-4713.
158. Chiarle R., Podda A., Prolla G., et al. CD30 in normal and neoplastic cells. Clin Immunol 1999, 90(2):157-164.
159. Sureda A., Constans M., Iriondo A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005, 16(4):625-633.
160. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363(19):1812-1821.
161. Chen R., Gopal A. Results of a pivotal phase 2 study of brentuximab vedontin (SGN-35) in patients with relapsed or refractory Hodgkin's lymphoma. Blood 2010, 116:128-129.
162. Foyil K.V., Kennedy D.A., Grove L.E., et al. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leuk Lymphoma 2012, 53(3):560-567.
163. Bartlett N., Grove L. Objective responses with brentuximab vedontin retreatment in CD30-positive hematologic malignancies: a case series. J Clin Oncol 2010, 28(Suppl 15). [abstract: 8062].
164. Katz J., Janik J.E., Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011, 17(20):6428-6436.
165. Aldinucci D., Gloghini A., Pinto A., et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221(3):248-263.
166. Lorusso P.M., Weiss D., Guardino E., et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011, 17(20):6437-6447.
167. Kaufman M., Rai K.R. Alemtuzumab in the up-front setting. Ther Clin Risk Manag 2008, 4(2):459-464.
168. Dyer M.J. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999, 26(5 Suppl 14):52-57.
169. Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol 2006, 33(2 Suppl 5):S44-S52.
170. Dearden C.E., Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol 2006, 19(4):795-810.
171. Kimby E. Management of advanced-stage peripheral T-cell lymphomas. Curr Hematol Malig Rep 2007, 2(4):242-248.
172. Lundin J., Hagberg H., Repp R., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003, 101(11):4267-4272.
173. Ricci F., Tedeschi A., Morra E., et al. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag 2009, 5(1):187-207.
174. Montillo M., Tedeschi A., Petrizzi V.B., et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood 2011, 118(15):4079-4085.
175. Grever M.R., Lucas D.M., Dewald G.W., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007, 25(7):799-804.
176. Stilgenbauer S., Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010, 2010:481-488.
177. Fiegl M., Erdel M., Tinhofer I., et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 2010, 21(12):2410-2419.
178. Stilgenbauer S., Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002, 347(6):452-453.
179. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103(9):3278-3281.
180. Stilgenbauer S., Zenz T., Winkler D., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009, 27(24):3994-4001.
181. Faderl S., Thomas D.A., O'Brien S., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003, 101(9):3413-3415.
182. Parikh S.A., Keating M.J., O'Brien S., et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011, 118(8):2062-2068.
183. Hainsworth J.D., Vazquez E.R., Spigel D.R., et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008, 112(6):1288-1295.
184. Schweighofer C.D., Ritgen M., Eichhorst B.F., et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009, 144(1):95-98.
185. Wierda W.G., Kipps T.J., Keating M.J., et al. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011, 117(1):116-124.
186. Lin T.S., Donohue K.A., Byrd J.C., et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010, 28(29):4500-4506.
187. Kipps T.J. Genomic complexity in chronic lymphocytic leukemia. Blood 2008, 112(5):1550.
188. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343(26):1910-1916.
189. Feng Y., Dimitrov D.S. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 2008, 11(2):178-185.
190. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007, 18(4):295-304.
191. Chen W., Dimitrov D.S. Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 2009, 4(2):112-117.
192. Chen W., Zhu Z., Feng Y., et al. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008, 382(3):779-789.
193. Dimitrov D.S. Engineered CH2 domains (nanoantibodies). MAbs 2009, 1(1):26-28.
194. Xiao X., Feng Y., Vu B.K., et al. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 2009, 387(2):387-392.
195. Gong R., Vu B.K., Feng Y., et al. Engineered human antibody constant domains with increased stability. J Biol Chem 2009, 284(21):14203-14210.
196. Gong R., Wang Y., Feng Y., et al. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal receptor. J Biol Chem 2011, 286(31):27288-27293.
197. Descotes J., Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008, 4(12):1537-1549.
198. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355(10):1018-1028.
199. Ewer S.M., Ewer M.S. Cardiotoxicity profile of trastuzumab. Drug Saf 2008, 31(6):459-467.
200. Chung C.H. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008, 13(6):725-732.
201. Winter M.C., Hancock B.W. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009, 8(2):223-235.
202. Pendley C., Schantz A., Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003, 5(2):172-179.
203. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008, 14:191-202.
204. Onda M. Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 2009, 10(2):131-139.
205. Baker M.P., Jones T.D. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 2007, 10(2):219-227.
206. Stas P., Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 2009, 12(3):169-173.
207. De Groot A.S., McMurry J., Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008, 8(5):620-626.
208. Emi Aikawa N., de Carvalho J.F., Artur Almeida Silva C., et al. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010, 38(2-3):82-89.
209. Hangartner L., Zinkernagel R.M., Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006, 6(3):231-243.
210. Dixit R., Coats S. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems. IDrugs 2009, 12(2):103-108.
211. Castillo J., Winer E., Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008, 36(7):755-768.
212. Mariani G., Fasolo A., De Benedictis E., et al. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009, 6(2):93-104.
213. Bedard P.L., Piccart-Gebhart M.J. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008, 8(Suppl 4):S157-S165.
214. Hall P.S., Cameron D.A. Current perspective-trastuzumab. Eur J Cancer 2009, 45(1):12-18.
215. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112(3):533-543.
216. Norden A.D., Drappatz J., Wen P.Y. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7(12):1152-1160.
217. Sachdev J.C., Jahanzeb M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 2008, 8(5):402-410.
218. Patel D.K. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008, 28(11 Pt 2):31S-41S.
219. Tassev D.V., Cheung N.K. Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 2009, 9(3):341-353.
220. Hopper-Borge E.A., Churchill T., Paulose C., et al. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009, 13(3):339-362.
221. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008, 20(4):460-470.
222. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8(3):226-234.
223. Labrijn A.F., Aalberse R.C., Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008, 20(4):479-485.
224. Kiewe P., Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 2008, 17(10):1553-1558.
225. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009, 58(5):823-830.
226. Yuan J., Gnjatic S., Li H., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008, 105(51):20410-20415.
227. Bellail A.C., Ling Q., Mulligan P., et al. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009, 4(1):34-41.
228. Feng Y., Xiao X., Zhu Z., et al. Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody. MAbs 2010, 2(5):565-570.
229. Zhang M.Y., Shu Y., Phogat S., et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 2003, 283(1-2):17-25.
230. Choudhry V., Zhang M.Y., Sidorov I.A., et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007, 363(1):79-90.
231. Zhang M.Y., Dimitrov D.S. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 2007, 13(2):203-212.
232. Liu H., Gaza-Bulseco G., Faldu D., et al. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008, 97(7):2426-2447.
233. Birch J.R., Racher A.J. Antibody production. Adv Drug Deliv Rev 2006, 58(5-6):671-685.
234. Zhou J.X., Tressel T., Yang X., et al. Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J 2008, 3(9-10):1185-1200.